Successful treatment of long-term, poststroke, upper-limb spasticity with onabotulinumtoxinA

Physical Therapy

Volumn 91, Issue 11, 2011, Pages 1636-1641

  Patel, Atul T ^a,b  

^a Kansas City Bone and Joint Clinic   (United States)

^b The Rehabilitation Institute of Kansas City   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ADULT; ARM; ARTICLE; CONVALESCENCE; FEMALE; HUMAN; OCCUPATIONAL THERAPY; PATHOPHYSIOLOGY; PHYSIOTHERAPY; SPASTICITY; STROKE; TREATMENT OUTCOME;

ADULT; ARM; BOTULINUM TOXINS, TYPE A; FEMALE; HUMANS; MUSCLE SPASTICITY; NEUROMUSCULAR AGENTS; OCCUPATIONAL THERAPY; PHYSICAL THERAPY MODALITIES; RECOVERY OF FUNCTION; STROKE; TREATMENT OUTCOME;

EID: 80355130027     PISSN: 00319023     EISSN: 15386724     Source Type: Journal    
DOI: 10.2522/ptj.20100370     Document Type: Article

References (28)

1. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119: 21-181
2. Watkins CL, Leathley MJ, Gregson JM, et al. Prevalence of spasticity post stroke. Clin Rehabil. 2002;16:515-522
3. Sommerfeld DK, Eek EU, Svensson AK, et al. Spasticity after stroke: its occurrence and association with motor impairments and activity limitations. Stroke. 2004;35: 134-139
4. Welmer AK, von Arbin M, Widén Holmqvist L, Sommerfeld DK. Spasticity and its association with functioning and health-related quality of life 18 months after stroke. Cerebrovasc Dis. 2006;21:247-253.
5. Lundström E, Terént A, Borg J. Prevalence of disabling spasticity 1 year after first-ever stroke. Eur J Neurol. 2008;15:533-539.
6. Urban PP, Wolf T, Uebele M, et al. Preva- lence and clinical predictors of spasticity after ischemic stroke. Cerebrovasc Dis. 2009;27(suppl 6):43.
7. Lance JW. The control of muscle tone, reflexes, and movement: Robert War-tenberg Lecture. Neurology. 1980;30: 1303-1313.
8. National Institute of Neurological Disorders and Stroke. NINDS Spasticity Information Page. 2007. Available at:http://www.ninds.nih.gov/disorders/spasticity/spasticity.htm. Accessed March 2011.
9. O'Brien CF. Treatment of spasticity with botulinum toxin. Clin J Pain. 2002;18(6 suppl):S182-S190
10. Cameron JI, Tsoi C, Marsella A. Optimizing stroke systems of care by enhancing transitions across care environments. Stroke. 2008;39:2637-2643.
11. Thompson AJ, Jarrett L, Lockley L, et al. Clinical management of spasticity. J Neurol Neurosurg Psychiatry. 2005;76:459-463.
12. National Stroke Association. Lack of Adequate Post-Stroke Care Unveiled. 2006. Available at: http://www.stroke.org/site/Survey_Highlights_final.pdf?docID1942. Accessed March 2011.
13. Duncan PW, Samsa GP, Weinberger M, et al. Health status of individuals with mild stroke. Stroke. 1997;28:740-745
14. Simpson DM, Gracies JM, Yablon SA, et al. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebocontrolled study. J Neurol Neurosurg Psy- chiatry. 2009;80:380-385.
15. Yablon SA. Botulinum neurotoxin intra-muscular chemodenervation: role in the management of spastic hypertonia and related motor disorders. Phys Med Rehabil Clin N Am. 2001;12:833-874.
16. Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache. 2003;43(suppl 1):16-24
17. Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002;347:395-400.
18. Elovic EP, Brashear A, Kaelin D, et al. Repeated treatments with botulinum toxin type A produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for care- givers and patients. Arch Phys Med Rehabil. 2008;89:799-806
19. Childers MK, Brashear A, Jozefczyk P, et al. Dose-dependent response to intra-muscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil. 2004;85: 1063-1069.
20. Simpson DM, Alexander DN, O'Brien CF, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebocontrolled trial. Neurology. 1996;46:1306-1310
21. Gordon MF, Brashear A, Elovic E, et al. Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology. 2004;63:1971-1973
22. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner. 1964;192:540-542
23. Viriyavejakul A, Vachalathiti R, Poungvarin N. Botulinum treatment for post-stroke spasticity: low dose regime. J Med Assoc Thai. 1998;81:413-422
24. Duncan PW, Zorowitz R, Bates B, et al. Management of adult stroke rehabilitation care: a clinical practice guideline. Stroke. 2005;36:e100-143
25. Heinemann AW. Special communications: state-of-the-science on postacute rehabilitation: setting a research agenda and devel- oping an evidence base for practice and public policy-an introduction. Top Stroke Rehabil. 2007;14:78-84.
26. National Stroke Association. New Survey Emphasizes Need for More, Better Care After Stroke. 2008. Available at: http://www.stroke.org/site/DocServer/NSA_Stroke_Perceptions_Survey_Press_Release_final_pdf?docID=1943. Accessed March 2011
27. Centers for Disease Control. Outpatient Rehabilitation Among Stroke Survivors: 21 States and the District of Columbia, 2005. 2007. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5620a4.htm. Accessed March 2011.
28. Brashear A, Lambeth K. Spasticity. Curr Treat Options Neurol. 2009;11:153-161